MiR-26 decreases atherosclerosis development in vivo by suppressing the expression of multiple genes, including ACC1, ACC2, ACLY, ACSL3, ACSL4, ALDH3A2, ALPL, BMP2, CD36, COL1A1, CPT1A, CTGF, DGAT2, EHHADH, FAS, FBP1, GATA4, GSK3β, G6PC, Gys2, HMGA1, HMGB1, LDLR, LIPC, IL-1β, IL-6, JAG2, KCNJ2, MALT1, β-MHC, NF-κB, PCK1, PLCβ1, PYGL, RUNX2, SCD1, SMAD1, SMAD4, SMAD5, SMAD7, SREBF1, TAB3, TAK1, TCF7L2, and TNF-α. The gene discussed is CCN2; the disease is atherosclerosis.